NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 109 filers reported holding NURIX THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,264,914 | -64.8% | 288,157 | -55.3% | 0.00% | -66.7% |
| Q2 2023 | $6,437,666 | +156954.5% | 644,411 | +39.6% | 0.00% | +50.0% |
| Q1 2023 | $4,099 | -31.8% | 461,592 | -15.7% | 0.00% | -33.3% |
| Q4 2022 | $6,010 | -99.9% | 547,335 | -26.0% | 0.00% | -50.0% |
| Q3 2022 | $9,641,000 | -6.3% | 739,925 | -8.9% | 0.01% | 0.0% |
| Q2 2022 | $10,287,000 | +100.5% | 811,928 | +121.7% | 0.01% | +100.0% |
| Q1 2022 | $5,131,000 | -70.3% | 366,232 | -38.6% | 0.00% | -66.7% |
| Q4 2021 | $17,262,000 | +143.2% | 596,286 | +151.7% | 0.01% | +125.0% |
| Q3 2021 | $7,097,000 | -37.2% | 236,883 | -44.4% | 0.00% | -42.9% |
| Q2 2021 | $11,301,000 | +51.5% | 425,986 | +77.5% | 0.01% | +40.0% |
| Q1 2021 | $7,460,000 | +100.4% | 239,935 | +111.9% | 0.01% | +66.7% |
| Q4 2020 | $3,722,000 | – | 113,204 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |